What is the @Official_ASAS recommended instrument for evaluating peripheral disease activity in axial and peripheral spondyloarthritis? 👉 DAPSA44 ✔️Good construct validity ✔️ High discriminatory capacity From the ASAS-Sparadise study #EULAR2026 @RheumNow https://t.co/Jbdvpn95jE

• https://x.com/Nellziade/status/2062908825376592209/photo/1

Not just ticking boxes! Prof. Rudwaleit on the revised 2025 ASAS/SPARTAN criteria for axSpA What’s new? Providing a stem so criteria will be applied only if w/SpA dx, not just imaging MRI:active inflamm + structural lesions Some SpA features omitted @RheumNow #EULAR2026 https://t.co/NCV0EFvjYa

• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1
• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1
• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1
• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1

Large French nationwide cohort (n=56,591 SpA patients) showed that >6 months/year of targeted therapy exposure was associated with reduced overall cancer risk (wHR 0.86), especially for haematological malignancies (wHR 0.65). Reassuring long-term safety signal. Abstr OP0238

The axSpA classification has been revised with the 2025 ASAS SPARTAN criteria. 5 abstracts at #EULAR2026 Abstr OP0236, OP0100, OP0239, POS0190 and POS1341. The single most important change in the 2025 criteria: MRI is now the highest-weighted variable and what counts as a https://t.co/xg4R4xRH2D

• https://x.com/synovialjoints/status/2062899406274179111/photo/1

SPARTAN-SSR: New quantitative criteria: BME in ≥3 consecutive slices OR any two of (BME, Erosion, Fat lesion each in ≥3 SIJ quadrants) or ankylosis in ≥3 halves achieves 88-96% sensitivity and 90-98% specificity across 3 cohorts. Precision #axSpA imaging. Abstr OP0100

Gecacitinib (pan-JAK inhibitor) vs placebo in radiographic #axSpA ASAS40 51.9% vs 12.9% (p<0.0001) at 16 weeks. ASAS20 69.2% vs 21.2% (p<0.0001). Pan-JAK inhibition showed efficacy in TNFi-experienced patients. Abstr OP0240 @RheumNow #EULAR2026

Does sequential therapy infliximab —> tofacitinib outperform tofa alone in axSpA? Yes: faster remission at week 4 (84.6% vs 15%) But: equal at week 24 Prospective study in 46 patients #POS0201 #EULAR2026 @RheumNow https://t.co/rmtoJQtYc0

• https://x.com/Nellziade/status/2062849233623908374/photo/1

Interesting poster #POS0939 from @SteZhao #EULAR2026 Long-term or recurrent antibiotic use in childhood associated w doubled risk of axSpA in HLA-B27+ individuals 11,611 HLA-B27+ UK biobank Recall bias? Yes but self-reported exposure validated with primary care data @RheumNow https://t.co/VmxI3BW6FE

• https://x.com/Nellziade/status/2062839948101722503/photo/1

In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP. At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+ POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr

• https://x.com/RHEUMarampa/status/2062829262353125624/photo/1

Double targeted therapy in refractory SpA/PsA. 76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics. Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit. ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX

• https://x.com/synovialjoints/status/2062799915672031405/photo/1

10yr ffup data on 49pts from the OG CRESPA study (GOL vs PBO in very early pSpA): 81.6% (40/49) were in clinical remission 15 pts on drug-free remission 21 pts w/remission on meds still on GOL, no unSSAEs Early aggressive tx is key! AbsPOS0931 @RheumNow #EULAR2026 https://t.co/HrTF5XtAZt

• https://x.com/RHEUMarampa/status/2062797311827210457/photo/1
• https://x.com/RHEUMarampa/status/2062797311827210457/photo/1

This study describes the SIJ differences in axSpA vs. non-axSpA pts with CBP axSpA: BME w/ widespread distribution & inflamm⬇️ over time non-axSpA: BME rare or limited only to ventral & middle superior sacrum Findings may improve MRI ID of axSpa AbsPOS0193 @RheumNow #EULAR2026 https://t.co/7eiHQOOIWs

• https://x.com/RHEUMarampa/status/2062657491662471252/photo/1

Gecacitinib 100mg BiD vs PBO in active r-axSpA: Met primary endpt ASAS40 at wk 16 showing efficacy of gecacitinib vs. PBO (51.9%vs12.9%,p<0.0001) Gecacitinib showed ⬆️ improvements in ASDAS-CRP, physical fnxn, spinal mobility & QOL Promising tx. AbsOP0240 @RheumNow #EULAR2026 https://t.co/FytoRgxvnG

• https://x.com/RHEUMarampa/status/2062650609497481580/photo/1
• https://x.com/RHEUMarampa/status/2062650609497481580/photo/1